|Abstract:||2-[R.sub.1 NHN(R)]-3-Q'-5-PY-6-Q-pyridines or pharmaceutically-acceptable acid-addition salts thereof are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, Q' is hydrogen or halo, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and R.sub.1 is hydrogen or when R is other than hydrogen R.sub.1 is the same as R. These compounds are prepared by reacting a 2-halo-3-Q'-5-PY-6-Q-pyridine with R.sub.1 NHNHR where 2-halo is bromo or chloro. Also shown are: the use of said 2-[R.sub.1 NN(R)]-3-Q'-5-PY-6-Q-pyridines as cardiotonic agents; and, the intermediates, 2,3-dihalo-5-PY-6-Q-pyridines, and their preparation from 3-nitro-5-PY-6-Q-2(1H)-pyridinones.|
|Inventor(s):|| Lesher; George Y. (Schodack, NY), Opalka, Jr.; Chester J. (Schodack, NY), Page; Donald F. (East Greenbush, NY) |
|Assignee:|| Sterling Drug Inc. (New York, NY) |
|Filing Date:||Nov 02, 1981|
|Claims:||1. A 2,3-dihalo-5-PY-6-Q-pyridine having the formula ##STR3## or pharmaceutically-acceptable acid-addition salt thereof, where halo is chloro or bromo, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, and Q is hydrogen or lower-alkyl. |
2. A compound according to claim 1 where halo is chloro, PY is 4-pyridinyl or 3-pyridinyl, and Q is hydrogen, methyl or ethyl.
3. The process which comprises reacting 3-nitro-5-PY-6-Q-2(1H)-pyridinone with a halogenating agent to produce 2,3-dihalo-5-PY-6-Q-pyridine according to claim 1 where halo is bromo or chloro, and PY and Q have the meanings given in claim 1.
4. The process according to claim 3 wherein halo is chloro, PY is 4-pyridinyl or 3-pyridinyl, and Q is hydrogen, methyl or ethyl.